Clinical and genomic characteristics of advanced urothelial carcinoma (UC) patients (pts) who fail therapy with enfortumab vedodin (EV) plus pembrolizumab (P).
Nataliya Mar(University of California, Irvine), Steven N. Seyedin(University of California, San Francisco), Amanda Macaraeg(University of California, Irvine), Suzanne M. Dufault(University of California, San Francisco), Mamta Parikh(UC Davis Comprehensive Cancer Center), M. Semaan(University of California, San Francisco), Alexandra Drakaki(UCLA Health), Ali Raad(Cancer Clinic), Neda Hashemi-Sadraei(University of New Mexico), Dimitrios Stefanoudakis(APLA Health)
Cited by 0
Related Papers
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78